AHA today voiced support for a number of proposed changes to the Medicare Advantage and Part D programs aimed at increasing plan negotiating power to lower drug prices, but emphasized “the importance of strong patient protections to ensure continuity of care, the application of medical necessity, an expedited appeals process, and required review and approval of MA step therapy plans by respective Pharmacy and Therapeutic Committees.” The proposed rule would allow Part D plans to exclude certain drugs from their formularies with the objective of negotiating lower drug prices; codify a recent change in policy that allowed MA plans to require beneficiaries to try cost-effective Part B drug therapies before progressing to more expensive options; require Part D plans to implement by 2020 electronic tools to inform prescribers of beneficiary-specific drug coverage and lower-cost therapeutic alternatives available to the enrollee; and require Part D plans to include information about changes in drug prices and lower-cost therapeutic alternatives in their explanation of benefits.

Related News Articles

Headline
The American Society for Health Care Engineering is supporting the ongoing efforts of hospital and health systems to fight COVID-19 in their communities by…
Headline
Community Health Improvement Week (June 1-5) celebrates people coming together to create healthier communities. And that's never been more important than now…
Headline
Thirty-three emerging hospital and health system leaders from 20 states will participate in the inaugural class of the AHA’s Next Generation Leaders Fellowship…
Headline
The Centers for Medicare & Medicaid Services yesterday released a fact sheet for state and local governments seeking Medicare, Medicaid or Children’s…
Headline
Over 1,750 Medicare Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have applied to offer lower insulin costs…
Headline
The Government Accountability Office today named three new members to the Medicare Payment Advisory Commission through April 2023. They are: Wayne…